Over the last few years, several papers have become available in the literature on both the main hallmarks of Alzheimer’s disease (AD) and the several intracellular pathways whose alteration is responsible for its onset and progression. The use of transgenic and nontransgenic animal models has played a key role in achieving such a remarkable amount of preclinical data, allowing researchers to dissect the cellular changes occurring in the AD brain. In addition, the huge amount of preclinical evidence arising from these animal models was necessary for the further clinical development of pharmacological agents capable of interfering with most of the impaired neural pathways in AD patients. In this respect, a significant role is played by the dysfunction of excitatory and inhibitory neurotransmission responsible for the cognitive and behavioral symptoms described in AD patients. The aim of this review is to summarize the main animal models that contributed toward unraveling the pathological changes in neurotransmitter synthesis, release, and receptor binding in AD preclinical studies. The review also provides an updated description of the current pharmacological agents – still under clinical development – acting on the neurotransmitter systems.

Mhillaj, E., Cuomo, V., Mancuso, C., The contribution of transgenic and nontransgenic animal models in Alzheimer’s disease drug research and development, <<BEHAVIOURAL PHARMACOLOGY>>, 2017; 28 (2 and 3 - Special Issue): 95-111. [doi:10.1097/FBP.0000000000000296] [http://hdl.handle.net/10807/97244]

The contribution of transgenic and nontransgenic animal models in Alzheimer’s disease drug research and development

Mancuso, Cesare
Ultimo
2017

Abstract

Over the last few years, several papers have become available in the literature on both the main hallmarks of Alzheimer’s disease (AD) and the several intracellular pathways whose alteration is responsible for its onset and progression. The use of transgenic and nontransgenic animal models has played a key role in achieving such a remarkable amount of preclinical data, allowing researchers to dissect the cellular changes occurring in the AD brain. In addition, the huge amount of preclinical evidence arising from these animal models was necessary for the further clinical development of pharmacological agents capable of interfering with most of the impaired neural pathways in AD patients. In this respect, a significant role is played by the dysfunction of excitatory and inhibitory neurotransmission responsible for the cognitive and behavioral symptoms described in AD patients. The aim of this review is to summarize the main animal models that contributed toward unraveling the pathological changes in neurotransmitter synthesis, release, and receptor binding in AD preclinical studies. The review also provides an updated description of the current pharmacological agents – still under clinical development – acting on the neurotransmitter systems.
Inglese
http://www.behaviouralpharm.com
Mhillaj, E., Cuomo, V., Mancuso, C., The contribution of transgenic and nontransgenic animal models in Alzheimer’s disease drug research and development, <>, 2017; 28 (2 and 3 - Special Issue): 95-111. [doi:10.1097/FBP.0000000000000296] [http://hdl.handle.net/10807/97244]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/97244
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact